XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Convertible Notes
Warrant
Common Stock
Common Stock
Convertible Notes
Common Stock
Warrant
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
Convertible Notes
Additional Paid-In Capital
Warrant
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2019         43,189,195                    
Beginning balance at Dec. 31, 2019 $ (24,532)       $ 3     $ 234,465       $ 54 $ (259,054)   $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Effect of exchange transaction (in shares)         (3,448,648)                    
Effect of exchange transaction (Note 13) (3,268)             (10,605)         7,337    
Cancellation of exchange transaction by shareholder (in shares)         184,520                    
Recognition of beneficial conversion feature related to convertible notes 1,629             1,629              
Issuance of warrants to purchase common stock 168             168              
Issuance of shares upon exercise of stock options and warrants (in shares)         277,718                    
Issuance of shares upon exercise of stock options and warrants 422       $ 1     421              
Stock-based compensation 4,542             4,542              
Unrealized loss on available-for-sale securities 0                            
Foreign currency translation adjustments (246)                     (246)      
Net loss (156,124)                       (156,124)    
Ending balance (in shares) at Dec. 31, 2020         40,202,785                    
Ending balance at Dec. 31, 2020 (177,409)       $ 4     230,620       (192) (407,841)   0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Merger and PIPE financing (Note 1) (in shares)         70,428,326                    
Merger and PIPE financing (Note 1) 248,144       $ 7     248,137              
Conversion of securities into common stock (in shares)           10,921,548 2,759,970                
Conversion of securities into common stock     $ 77,748 $ 60,568   $ 1       $ 77,747 $ 60,568        
Exchange of warrants into common stock (Note 14) (in shares)         4,683,349                    
Exchange of warrants into common stock (Note 14) 168,647       $ 1     168,646              
Issuance of common stock warrants for services (Note 14) 9,183             9,183              
Public Warrants exercises (Note 14) (in shares)         12,638,723                    
Public Warrants exercises (Note 14) 312,116       $ 1     312,115              
Issuance of 2028 Convertible Notes, net (Note 13) 130,979             130,979              
Purchase of capped call options (Note 13) (66,700)             (66,700)              
Legacy stock warrant exercises (Note 14) (in shares)         369,539                    
Legacy stock warrant exercises (Note 14) 418             418              
Stock option exercises, net of statutory tax withholdings (in shares)         2,667,384                    
Stock option exercises, net of statutory tax withholdings (9,574)             (9,574)              
Stock-based compensation 14,706             14,706              
Unrealized loss on available-for-sale securities (175)                     (175)      
Foreign currency translation adjustments 387                     387      
Net loss (101,211)                       (101,211)    
Ending balance (in shares) at Dec. 31, 2021         144,671,624                    
Ending balance at Dec. 31, 2021 667,827       $ 14     1,176,845       20 (509,052)   0
Ending balance (Accounting Standards Update 2020-06) at Dec. 31, 2021   $ (129,381)             $ (130,979)         $ 1,598  
Ending balance (Accounting Standards Update 2016-13) at Dec. 31, 2021   $ (573)                       $ (573)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Common stock issued upon business combination (Note 6) (in shares)         8,621,006                    
Common stock issued upon business combination (Note 6) $ 108,883       $ 1     108,882              
Stock option exercises, net of statutory tax withholdings (in shares) 1,512,719       1,019,552                    
Stock option exercises, net of statutory tax withholdings $ (1,178)             (1,178)              
Issuance of common stock upon release of restricted stock units (in shares)         206,914                    
Shares issued for exercise of warrants (in shares)         21,101                    
Shares issued for exercise of warrants 150             150              
Stock-based compensation 31,644             31,644              
Unrealized loss on available-for-sale securities (1,507)                     (1,507)      
Foreign currency translation adjustments (185)                     (185)      
Contributions from non-controlling interests 541                           541
Net loss (124,054)                       (124,054)    
Ending balance (in shares) at Dec. 31, 2022         154,540,197                    
Ending balance at Dec. 31, 2022 $ 552,167       $ 15     $ 1,185,364       $ (1,672) $ (632,081)   $ 541